Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. reports developments as a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors. Its news centers on oncology programs including CTIM-76, a CLDN6 x CD3 bispecific antibody; CT-95, a MSLN x CD3 bispecific antibody; and CT-202, a Nectin-4 x CD3 bispecific antibody.
Recurring updates cover clinical and preclinical data, regulatory designations, scientific conference presentations, operating results, research and development spending, liquidity, investor-conference activity and equity-based employee inducement grants. CTIM-76 has received FDA Fast Track designation for platinum-resistant ovarian cancer, adding regulatory status to the company's solid-tumor development disclosures.
Context Therapeutics (Nasdaq: CNTX) granted a non-qualified stock option to purchase 146,000 shares of common stock to a new employee as an employment inducement under Nasdaq Listing Rule 5635(c)(4). The award was granted outside the company’s 2021 Long-Term Performance Incentive Plan.
According to Context Therapeutics, the option was granted on the employee’s hire date, July 7, 2026, with an exercise price of $0.70 per share, equal to the Nasdaq closing price on the grant date. The stock option has a 10-year term and vests over four years: one-fourth on the first anniversary of the grant date and the remaining shares in 36 equal monthly installments, subject to continued service.
Context Therapeutics (Nasdaq:CNTX), a clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors, has been added to the Russell 2000 and Russell 3000 indexes.
Inclusion became effective after U.S. market close on June 26, 2026, aligning CNTX with widely used U.S. equity benchmarks.
Context Therapeutics (Nasdaq:CNTX) reported positive interim Phase 1a data for CTIM-76, a CLDN6 x CD3 T cell engager, in advanced platinum-resistant ovarian cancer (PROC).
Among efficacy-evaluable PROC patients at active doses, ORR was 29%, DCR 57%, with ≥6-month disease control in three patients and predominantly low-grade, reversible adverse events. CTIM-76 has FDA Fast Track in PROC, and PK supports Q3W dosing starting 2H 2026.
Context Therapeutics (Nasdaq:CNTX) granted a non-qualified stock option to a new employee as an inducement award under Nasdaq Listing Rule 5635(c)(4). The option covers 146,000 shares at an exercise price of $1.71, has a 10-year term, and vests over four years, subject to continued service.
Context Therapeutics (Nasdaq:CNTX) will present at the Jefferies Global Healthcare Conference in New York on June 3, 2026, at 7:35 a.m. ET, with a live webcast and 90-day replay on its investor website.
Context also granted a Nasdaq Rule 5635(c)(4) inducement stock option for 146,000 shares to a new employee, priced at $2.63 per share, with a 10-year term and four-year vesting schedule.
Context Therapeutics (Nasdaq:CNTX) amended its exclusive license with BioAtla for CT-202, its Nectin-4 x CD3 T cell engager. The amendment converts the license into a fully paid-up, non-terminable agreement, eliminating all future CT-202 milestones and royalties in exchange for $4.5 million upfront and a final $2.0 million payment due by August 1, 2026. Phase 1 initiation for the CT-202 trial is expected in the third quarter of 2026.
Context Therapeutics (Nasdaq: CNTX) reported Q1 2026 results and pipeline milestones. Cash and cash equivalents were $54.5 million as of March 31, 2026, expected to fund operations into mid-2027. Phase 1a interim data for CTIM-76 expected June 2026 and for CT-95 expected September 2026. CT-202 first-in-human initiation is anticipated in Q3 2026 after Australian HREC and TGA CTN acknowledgements. FDA granted Fast Track Designation to CTIM-76 in April 2026. Q1 R&D expense was $7.0 million; net loss was $8.7 million.
Neogen (NASDAQ:NEOG) appointed Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary effective immediately. Ms. Stacey brings more than 25 years of life sciences legal and compliance experience, including over 10 years as a public company chief legal officer and 5 years as a public company board member.
She previously served at Galera Therapeutics and held senior legal roles at Wistar Institute, Antares Pharma, FXI, Auxilium, and Aventis Behring. Ms. Stacey also serves on the board of Context Therapeutics (NASDAQ:CNTX).
Context Therapeutics (Nasdaq: CNTX) announced that the FDA granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for treatment of platinum-resistant ovarian cancer (PROC).
CTIM-76 is in a Phase 1 trial evaluating safety, tolerability, pharmacokinetics and anti-tumor activity in CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers. The company expects interim Phase 1a data in June 2026.
Context Therapeutics (Nasdaq: CNTX) reported full-year 2025 results and pipeline updates. The company had $66.0 million cash at December 31, 2025, and expects runway into mid-2027. CTIM-76 Phase 1a interim data expected June 2026; CT-95 Phase 1a interim data expected September 2026. CT-202 regulatory filings completed and first patient dosing expected in Q3 2026. 2025 R&D expense was $31.9M and net loss was $36.1M.